Info

Bone Biologics (The Company) is a convergence Biotechnology Company focused in the Orthobiologics space. The Company was founded by University of California, Los Angeles (UCLA) professors in 2004. The target markets for the unique UCB-1TM protein-based technologies of the Company are bone and cartilage regeneration. The Platform Technology has application in delivering improved outcomes in the surgical specialties of spinal, orthopedic, general orthopedic, plastic reconstruction, neurosurgery, interventional radiology, and sports medicine. Lead product development and clinical studies are targeted on spinal fusion surgery, a rapidly growing market space currently underserved by outcome enhancements. The UCB-1TM technology has met and surpassed existing standards of care outcomes in ongoing studies.